Argenx Slumps 15% After Bleeding Disorder Drug Study Disappoints

1
Comment
Favorite

Argenx Slumps 15% After Bleeding Disorder Drug Study Disappoints

Bloomberg2023-11-28

Shares drop as much as 17%, their biggest decline everPatients fared better on placebo than on the medicine in trialArgenx SE shares plunged after the Dutch biotech said preliminary results from a ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

No comments yet

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/1114001887?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2023-11-28 17:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1114001887","market":"us","top_or_hot":-1,"title":"Argenx Slumps 15% After Bleeding Disorder Drug Study Disappoints","media":"Bloomberg","content":"<div>\n<p>Shares drop as much as 17%, their biggest decline everPatients fared better on placebo than on the medicine in trialArgenx SE shares plunged after the Dutch biotech said preliminary results from a ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2023-11-28/argenx-slumps-after-its-only-drug-disappoints-in-study\">Source Link</a>\n\n</div>\n","source":"lsy1584095487587","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Argenx Slumps 15% After Bleeding Disorder Drug Study Disappoints</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nArgenx Slumps 15% After Bleeding Disorder Drug Study Disappoints\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-11-28 17:11 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2023-11-28/argenx-slumps-after-its-only-drug-disappoints-in-study><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares drop as much as 17%, their biggest decline everPatients fared better on placebo than on the medicine in trialArgenx SE shares plunged after the Dutch biotech said preliminary results from a ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2023-11-28/argenx-slumps-after-its-only-drug-disappoints-in-study\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ARGX","symbol_name":"Argenx SE","start_time":0,"source_url":"https://www.bloomberg.com/news/articles/2023-11-28/argenx-slumps-after-its-only-drug-disappoints-in-study","article_id":"1114001887","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1114001887","pubTimestamp":1701162664,"sourceInfo":{"source_id":"lsy1584095487587","name":"Bloomberg"},"weMediaInfo":null,"summary":"Shares drop as much as 17%, their biggest decline everPatients fared better on placebo than on the medicine in trialArgenx SE shares plunged after the Dutch biotech said preliminary results from a stu","collect":0,"end_time":0,"defaultTopTitle":"bloomberg.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"ARGX":"Argenx SE"},"translate_title":"出血性疾病药物研究令人失望后，Argenx下跌15%","themeId":"c5bbfdf5f7964880af97c1d6f417052c","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARGX":1.1},"content_text":"Shares drop as much as 17%, their biggest decline everPatients fared better on placebo than on the medicine in trialArgenx SE shares plunged after the Dutch biotech said preliminary results from a study suggest its only medicine failed in a trial for a rare bleeding disorder.Fewer volunteers taking the drug, Vyvgart, had improved blood clotting than those taking a placebo in a study, the company said Tuesday. The patients suffered from primary immune thrombocytopenia, in which insufficient platelets lead to bleeding, bruising and fatigue.The stock fell as much as 15% in early trading, dropping to the lowest level in four months.The setback comes as Argenx tests Vyvgart, the first of a new class of medicines that prevent a common antibody from being recycled back into the blood, for more than a dozen rare conditions.“This is not the outcome we had hoped for patients, but setbacks are part of pioneering a new class of medicines,” said Luc Truyen, the company’s chief medical officer.The results announced Tuesday appear to conflict with another study testing the drug for primary immune thrombocytopenia, which showed it helped patients.What Bloomberg Intelligence Says:The failure of Argenx’s trial is unexpected, especially since the company had increased its size to improve the chances of success, and given positive data for the intravenous formulation. The bust likely rules out US approval, and will weigh on consensus’ $4 billion of Vyvgart sales in 2027.— Michael Shah, BI pharma analystFor now, Vyvgart is approved to treat a progressive nerve disease known as myasthenia gravis. Argenx is scheduled to release results from another trial, for the rare blister-causing disease pemphigus vulgaris, toward the end of the year.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}